The Food and Drug Administration on Wednesday approved a new weight loss pill from drugmaker Eli Lilly. The daily pill, called Foundayo, is the second oral GLP-1 to reach the market in recent months, following the approval of Novo Nordisk’s Wegovy pill in December. Foundayo will be offered in six doses, with patients typically starting on the lowest dose and working their way up to reduce side effects. It can be taken at any time of day […]

Hormones play a role too. When an individual tries to lose weight, it triggers a powerful hormonal response that tells your body to regain the weight you lost. Cummings explains that because of this, the brain interprets a calorie drop as an energy deficiency, so after stopping weight-loss drugs, hormones that stimulate appetite increase while the rate at which you burn energy – the metabolic rate – decreases. “If these biological defences are strong enough, they can […]

Overview of study recruitment Participants in this study were recruited from the customer base of 23andMe. Participants provided informed consent and volunteered to participate in the research online, under a protocol approved by the external Association for the Accreditation of Human Research Protection Programs-accredited Salus Institutional Review Board (https://www.versiticlinicaltrials.org/salusirb). Participants were included in the analysis on the basis of consent status verified at the time data analyses were initiated. The 23andMe GLP1 survey was launched to research […]

  Key Insights The current range of weight-loss drugs on the market targets GLP-1 receptors. Seeking a new generation of weight-loss drugs, some companies are developing amylin analogs. As clinical trial data around amylin analogs emerge, investors worry about the amount of weight loss the molecules can offer. For the past 7 years, pharmaceuticals that work as glucagon-like peptide 1 (GLP-1) receptor agonists have dominated the weight-loss and diabetes markets. These drugs, currently sold by Novo Nordisk […]